ESMO is a European meeting that belongs on a US oncology seller's calendar anyway. Many US-headquartered biotech and pharma companies use it for the same partnering and data-release purposes they use ASCO for, so who exhibits and presents there is a real read on active oncology programs, even though the doors open in Madrid rather than Chicago.
What ESMO is
The ESMO Congress, run by the European Society for Medical Oncology, is one of the largest clinical oncology meetings in the world and the closest European counterpart to ASCO. It draws medical oncologists, trial sponsors, and effectively every company running or supporting an oncology program, alongside the CROs, CDMOs, and specialty labs that serve them. A large share of exhibitors and presenters are US-headquartered companies that treat ESMO as a core annual stop rather than a purely regional one.
The GTM signal at ESMO
Exhibiting at ESMO carries the same strongest-signal logic as any major show: a booth reflects budget committed months ahead to being visible in front of an oncology audience. A named presenter tied to a specific dataset is an equally sharp contact-level hook. For a US seller, the useful nuance is that ESMO presence often signals a company operating an oncology program with a European or global footprint, which can be a helpful qualifier on top of the domestic picture. See selling around life science conferences for how to weigh exhibiting, presenting, and attending.
The outreach window
Accepted abstracts and exhibitor lists become public in the weeks before ESMO, the same pre-show pattern as the flagship US oncology meetings, giving a lead-time window to cross-reference the roster against your oncology account list and plan specific outreach before the congress opens. Because the venue is in Europe, some US teams work the show remotely rather than traveling, using the published lists and data to time outreach around the meeting rather than staffing a booth. The useful follow-up window after ESMO closes runs a few weeks before a reference to the meeting stops reading as current.
Who this matters most for
A CRO running or pursuing oncology trials should track ESMO alongside ASCO, since the presenting-company overlap is large and the European footprint is itself a useful qualifier. A CDMO supporting oncology programs will find many of the same accounts here as at the domestic shows. A tools or services vendor serving oncology research and development can use ESMO to catch programs with a global presence that a US-only view might under-weight.